Clinical Trials Logo

Filter by:
NCT ID: NCT06203990 Active, not recruiting - Parkinson Disease Clinical Trials

Barre Exercise in Parkinson's

Start date: January 2, 2024
Phase: Phase 1
Study type: Interventional

This study asks if a barre exercise program is a feasible and acceptable form of exercise for individuals with Parkinson disease. The study will also evaluate barre's potential effects on motor outcomes, including balance, strength, and functional mobility.

NCT ID: NCT06203756 Active, not recruiting - Clinical trials for Arthroplasties, Knee Replacement

Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty

Start date: November 9, 2017
Phase: N/A
Study type: Interventional

The goal of this study is to learn about the effects of soft tissue balancing technology in patients undergoing robotic assisted total knee arthroplasty (TKA). The main questions it aims to answer are: - What is the accuracy of soft tissue balancing in both sensor assisted and non-sensor assisted TKA - What are the outcomes of a cohort of TKA patients who undergo surgery with soft tissue balance technology Participants will answer health related surveys both before and after their surgery.

NCT ID: NCT06201689 Active, not recruiting - Fatigue Clinical Trials

Radicle Energy 24: A Study of Health and Wellness Products on Fatigue and Related Health Outcomes

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on fatigue and related health outcomes

NCT ID: NCT06200012 Active, not recruiting - Clinical trials for Substance Use Disorders

Multi-Level Stigma Intervention for Mental Health Services

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

This cluster randomized trial develops and pilot tests a multi-level substance use stigma intervention that leverages organizational policy and professional education to address structural and professional drivers of stigma in outpatient mental health (MH) services. The investigators will generate preliminary data to determine whether adding an organizational policy to a professional stigma training may reduce measures of provider-based stigma towards substance use and improve care quality and patient outcomes to a greater degree than simply conducting training alone. The investigators hypothesize that providers at a MH site implementing an organizational policy change in addition to providing professional training will demonstrate greater improvement to health services for people who use drugs compared to a site where providers receive training alone.

NCT ID: NCT06199934 Active, not recruiting - SARS-CoV-2 Clinical Trials

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Start date: February 7, 2024
Phase:
Study type: Observational

The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.

NCT ID: NCT06198686 Active, not recruiting - Healthy Clinical Trials

An Evaluation of The Absolute Bioavailability of TH104

Start date: January 26, 2024
Phase: Phase 1
Study type: Interventional

This is a single-dose, single-center, open-label, randomized, 2-way crossover study (2 treatments, 2 periods and 2 sequences) of a buccal formulation of Nalmefene 16 mg and a 1 mg intravenous dose of nalmefene injection, with a least 7 days washout period between doses.

NCT ID: NCT06193759 Active, not recruiting - Clinical trials for Medulloblastoma, Childhood

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

IMPACT
Start date: June 4, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues. Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors. Correlative biological studies will measure clinical anti-tumor, immunological and biomarker effects.

NCT ID: NCT06192550 Active, not recruiting - Wrinkle Clinical Trials

Functional Usability and Feasibility Testing of the Profound Matrix™ System

Start date: October 28, 2020
Phase: N/A
Study type: Interventional

This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up to five (5) treatments with the Sublime and/or Sublative Radiofrequency (RF) applicators.

NCT ID: NCT06191991 Active, not recruiting - Healthy Volunteers Clinical Trials

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

Start date: November 3, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomitant drugs: atorvastatin (Part 1), or rosuvastatin (Part 2, optional).

NCT ID: NCT06189066 Active, not recruiting - Long Covid Clinical Trials

Long COVID Ultrasound Trial

LOCUS
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study. Specific Aims include: - Measure Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation. - Measure molecular correlates of Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation. - Track adverse events throughout the study to assess safety of the ultrasound intervention.